Polycystic Ovarian Syndrome. Polycystic ovarian syndrome
Conditions
Interventions
Intervention 1: Intervention group: 25 eligible patients will receive 12 mg of astaxanthin (AstaZine®, from BGG) daily (one 4 mg capsule, every 8 hours) for 6 weeks until the day before the ovarian pu
Sponsors
Tehran University of Medical Sciences
Eligibility
Sex/Gender
Female
Age
18 Years to 40 Years
Inclusion criteria
Inclusion criteria: Aged between 18 to 40 years old Body mass index (BMI): 20-30 Polycystic ovary syndrome (PCOS) diagnosis based on the Rotterdam criteria Assisted reproductive technology (ART) candidate due to anovulatory infertility Controlled ovulation stimulation (COS) by GnRH-Antagonist protocol
Exclusion criteria
Exclusion criteria: Pregnancy or abortion during last year before the start of the study History of other endocrinopathies such as adrenal hyperplasia, androgen-secreting tumors, hyperprolactinemia, thyroid dysfunction, diabetes, or impaired glucose tolerance Coexistence of other causes of infertility (severe male factor, tubal factor, uterine factor, endometriosis, Asherman syndrome, diminished ovarian reserves, etc.) Consumption of herbal or traditional medicine, antioxidant supplements, and vitamins within three months before the start of the study Taking ovulation-induction drugs, hormonal agents, and metformin within three months before the start of the study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Oocyte Maturity Rate (Number of mature oocytes (Metaphase II) : Total oocytes). Timepoint: 6 weeks after the start of the intervention (oocyte retrieval day). Method of measurement: Light microscope examination.;Number of high quality embryos. Timepoint: 3 days after intracytoplasmic sperm injection (ICSI). Method of measurement: Observation of male and female pronuclei (2PN) with light microscope.;Markers of AMPK-Autophagy signaling pathway (including AMPK, pAMPK, CL3-I, CL3-II, and SQSTM/P62 proteins and Beclin-1 and ATG7 genes). Timepoint: 6 weeks after the start of the intervention (oocyte retrieval day). Method of measurement: Western Blotting and realtime-qPCR. | — |
Secondary
| Measure | Time frame |
|---|---|
| Chemical Pregnancy Rate. Timepoint: Two weeks after embryo transfer. Method of measurement: BhCG test.;Clinical Pregnancy Rate. Timepoint: 6-8th week of gestational age. Method of measurement: observation of the gestational sac or heartbeat on ultrasound.;Miscarriage Rate. Timepoint: Early miscarriage until 12 weeks and late miscarriage until 20 weeks of gestation. Method of measurement: Ultrasound.;Ongoing Pregnancy Rate. Timepoint: until 20 weeks of gestation. Method of measurement: Ultrasound.;Apoptosis Markers in Granulosa Cells (including intact PARP and cleaved PARP proteins). Timepoint: 6 weeks after the start of the intervention (oocyte retrieval day). Method of measurement: Western Blotting. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactArezoo Maleki-Hajiagha
Tehran University of Medical Sciences
Outcome results
None listed